<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
<channel>
                    <title>Urology</title>
            <link>https://medicalxpress.com/urology-news/</link>
            <language>en-us</language> 
            <description>Latest medical news and research in Urology</description>

                            <item>
                    <title>What men need to know after a major update to prostate cancer guidelines</title>
                    <description>Middle-aged men should undergo regular screening for prostate cancer, the American Cancer Society said Thursday in a major change to its guidelines.</description>
                    <link>https://medicalxpress.com/news/2026-11-men-major-prostate-cancer-guidelines.html</link>
                    <category></category>
                    <pubDate>Fri, 13 Nov 2026 05:00:04 EST</pubDate>
                    <guid isPermaLink="false">news713765862</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/prostate-cancer-screen.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New guidelines recommend regular prostate cancer screening for all middle-aged men</title>
                    <description>Experts now recommend regular prostate cancer screening for all men ages 50 to 69 and earlier for higher-risk groups, according to new American Cancer Society (ACS) guidelines.</description>
                    <link>https://medicalxpress.com/news/2026-11-guidelines-regular-prostate-cancer-screening.html</link>
                    <category></category>
                    <pubDate>Thu, 12 Nov 2026 13:20:15 EST</pubDate>
                    <guid isPermaLink="false">news713707416</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/man-at-doctors-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>A blood test could help identify men with advanced prostate cancer most likely to benefit from targeted radiotherapy</title>
                    <description>A blood test could help identify men with advanced prostate cancer who are more likely to experience longer disease control following targeted radiotherapy, according to research led by The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London and University College London. The findings are published in the journal JAMA Network Open.</description>
                    <link>https://medicalxpress.com/news/2026-11-blood-men-advanced-prostate-cancer.html</link>
                    <category></category>
                    <pubDate>Thu, 12 Nov 2026 04:00:01 EST</pubDate>
                    <guid isPermaLink="false">news713678292</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/a-blood-test-could-hel.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Molecular brace traps two cancer-driving proteins to suppress prostate cancer growth in preclinical tests</title>
                    <description>Many modern cancer drugs typically target a specific protein or signaling pathway to treat tumors. Now, researchers at the University of Michigan Health Rogel Cancer Center are taking a new approach by throwing a molecular wrench into the machinery driving prostate cancer. In preclinical studies, this new approach demonstrated greater antitumor activity while sparing normal cells.</description>
                    <link>https://medicalxpress.com/news/2026-11-molecular-brace-cancer-proteins-suppress.html</link>
                    <category></category>
                    <pubDate>Wed, 11 Nov 2026 11:00:01 EST</pubDate>
                    <guid isPermaLink="false">news713614021</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/a-new-anti-cancer-stra.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Prostate cancer drug combination adds toxicity without clear benefit for tumors lacking targetable mutations</title>
                    <description>The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d&#039;Hebron Institute of Oncology&#039;s (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi) talazoparib versus enzalutamide alone in patients with high-tumor-burden metastatic prostate cancer who had not previously received hormone therapy.</description>
                    <link>https://medicalxpress.com/news/2026-11-prostate-cancer-drug-combination-toxicity.html</link>
                    <category></category>
                    <pubDate>Tue, 10 Nov 2026 17:20:08 EST</pubDate>
                    <guid isPermaLink="false">news713545981</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/prostate-cancer-drug-c.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New drug combination improves survival in patients with muscle-invasive bladder cancer</title>
                    <description>A new treatment approach could help people with an aggressive form of bladder cancer live longer and reduce the chances of their cancer returning or progressing, particularly those who cannot receive standard chemotherapy, according to findings from a large international clinical trial co-led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center.</description>
                    <link>https://medicalxpress.com/news/2026-11-drug-combination-survival-patients-muscle.html</link>
                    <category></category>
                    <pubDate>Mon, 09 Nov 2026 18:30:01 EST</pubDate>
                    <guid isPermaLink="false">news713457716</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/hand-on-bladder.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Study challenges long-held fears about overactive bladder drugs and dementia</title>
                    <description>New research published in JAMA Network Open finds anticholinergic medications, commonly prescribed for overactive bladder (OAB), may not increase dementia risk after all compared to beta-3 agonists, the newer drug class that has been presumed to be safer for the brain.</description>
                    <link>https://medicalxpress.com/news/2026-11-held-overactive-bladder-drugs-dementia.html</link>
                    <category></category>
                    <pubDate>Mon, 09 Nov 2026 10:20:08 EST</pubDate>
                    <guid isPermaLink="false">news713441204</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2022/dementia-6.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Prostate cancer drug shows promise in new clinical trial</title>
                    <description>In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity and pain for patients with metastatic prostate cancer.</description>
                    <link>https://medicalxpress.com/news/2026-11-prostate-cancer-drug-clinical-trial.html</link>
                    <category></category>
                    <pubDate>Wed, 04 Nov 2026 10:40:20 EST</pubDate>
                    <guid isPermaLink="false">news713008659</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/prostate-cancer-drug-s.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Researchers identify critical window for boosting immunotherapy response in prostate cancer</title>
                    <description>Researchers at Roswell Park Comprehensive Cancer Center have shown that hormone-blocking therapies commonly used to treat prostate cancers temporarily activate the body&#039;s immune response before those immune effects begin to fade over time. In a new publication in the Journal for Immunotherapy of Cancer, a team led by Kent Nastiuk, Ph.D., reports this discovery—and points the way to a treatment strategy for taking advantage of this window of opportunity.</description>
                    <link>https://medicalxpress.com/news/2026-10-critical-window-boosting-immunotherapy-response.html</link>
                    <category></category>
                    <pubDate>Thu, 29 Oct 2026 08:20:25 EDT</pubDate>
                    <guid isPermaLink="false">news712480025</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/researchers-identify-c-8.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Combining targeted therapies significantly boosted survival in kidney cancer study</title>
                    <description>Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP, professor of oncology in the Department of Medicine, is principal investigator of the trial and first author of the study, newly published in The Lancet Oncology.</description>
                    <link>https://medicalxpress.com/news/2026-10-combining-therapies-significantly-boosted-survival.html</link>
                    <category></category>
                    <pubDate>Wed, 28 Oct 2026 14:40:01 EDT</pubDate>
                    <guid isPermaLink="false">news712413506</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/combining-2-vegf-block.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Diagnostic test could help doctors refine prostate cancer treatment</title>
                    <description>Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act between identifying patients who will benefit from more intensive treatment and those who may do just as well without it. Treating someone more aggressively than necessary is associated with increased side effects and poorer quality of life.</description>
                    <link>https://medicalxpress.com/news/2026-10-diagnostic-doctors-refine-prostate-cancer.html</link>
                    <category></category>
                    <pubDate>Fri, 23 Oct 2026 20:40:01 EDT</pubDate>
                    <guid isPermaLink="false">news711972301</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/genomic-test.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New AI platform helps uncover promising cancer drug combinations</title>
                    <description>UCLA investigators have developed a new artificial intelligence-based platform that could help scientists identify promising drug combinations to overcome treatment resistance in cancer.</description>
                    <link>https://medicalxpress.com/news/2026-10-ai-platform-uncover-cancer-drug.html</link>
                    <category></category>
                    <pubDate>Thu, 22 Oct 2026 16:00:20 EDT</pubDate>
                    <guid isPermaLink="false">news711898983</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2024/cancer.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>DNA once dismissed as &#039;noise&#039; reveals new bacterial species in prostate cancer patients</title>
                    <description>University of East Anglia researchers have discovered the genetic blueprints of 18 new bacterial species collected from prostate cancer patients.</description>
                    <link>https://medicalxpress.com/news/2026-10-dna-dismissed-noise-reveals-bacterial.html</link>
                    <category></category>
                    <pubDate>Mon, 19 Oct 2026 19:00:06 EDT</pubDate>
                    <guid isPermaLink="false">news711634023</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2019/5-bacteria.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Targeted radiation shows promise for life-threatening kidney cancer complication</title>
                    <description>When Diane Gentry, a 71-year-old retiree from Watauga, Texas, was diagnosed with stage 4 kidney cancer in 2015, she learned the tumor had grown into her inferior vena cava, the body&#039;s largest vein. This potentially life-threatening complication can require extensive surgery and carries a high risk of cancer recurrence.</description>
                    <link>https://medicalxpress.com/news/2026-10-life-threatening-kidney-cancer-complication.html</link>
                    <category></category>
                    <pubDate>Sun, 18 Oct 2026 11:20:08 EDT</pubDate>
                    <guid isPermaLink="false">news711367149</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/targeted-radiation-sho.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Genomic cancer driver study reveals new clues to why some prostate cancers become aggressive</title>
                    <description>Why do some prostate cancers grow slowly for years, while others progress quickly to life-threatening metastatic disease? An international team of researchers co-led by the Ontario Institute for Cancer Research (OICR) and the University of Copenhagen has uncovered new clues in the genomes of prostate cancers.</description>
                    <link>https://medicalxpress.com/news/2026-10-genomic-cancer-driver-reveals-clues.html</link>
                    <category></category>
                    <pubDate>Fri, 16 Oct 2026 16:20:09 EDT</pubDate>
                    <guid isPermaLink="false">news711376921</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/genomic-cancer-driver.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Same duty cycle, very different outcomes: What tough materials taught us about histotripsy</title>
                    <description>One of the questions that stayed with me throughout my Ph.D. was surprisingly simple: Why are some tissues so much harder to break down with histotripsy than others? Histotripsy is a focused ultrasound technique that uses cavitation bubbles to mechanically break down tissue. Unlike thermal ablation, the goal is not to heat the tissue. Instead, the rapid activity of these bubbles creates mechanical stresses that progressively disrupt tissue structure.</description>
                    <link>https://medicalxpress.com/news/2026-10-duty-outcomes-tough-materials-taught.html</link>
                    <category></category>
                    <pubDate>Mon, 12 Oct 2026 22:00:01 EDT</pubDate>
                    <guid isPermaLink="false">news711029688</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/same-duty-cycle-very-d-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer</title>
                    <description>A new study revealed molecular features linked to more aggressive prostate cancer in a subset of patients who had been classified as low risk, highlighting biological differences that may not be apparent from clinical measures alone. The results could lead to new therapeutic strategies.</description>
                    <link>https://medicalxpress.com/news/2026-10-prostate-tumors-reveal-molecular-linked.html</link>
                    <category></category>
                    <pubDate>Wed, 07 Oct 2026 16:40:06 EDT</pubDate>
                    <guid isPermaLink="false">news710605686</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/low-risk-prostate-tumo.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Key driver of aggressive prostate cancer identified, suggesting new way to reverse drug resistance</title>
                    <description>Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.</description>
                    <link>https://medicalxpress.com/news/2026-10-key-driver-aggressive-prostate-cancer.html</link>
                    <category></category>
                    <pubDate>Wed, 07 Oct 2026 11:00:02 EDT</pubDate>
                    <guid isPermaLink="false">news710522401</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/key-driver-of-aggressi.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>RNA urine test outperforms standard bladder cancer tests and could help guide treatment</title>
                    <description>A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods. The test also allows physicians not only to assess the cancer&#039;s response to treatment but also to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.</description>
                    <link>https://medicalxpress.com/news/2026-10-rna-urine-outperforms-standard-bladder.html</link>
                    <category></category>
                    <pubDate>Fri, 02 Oct 2026 05:00:01 EDT</pubDate>
                    <guid isPermaLink="false">news710067602</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/urine-test-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Combination therapy emerges as possible treatment for an aggressive form of kidney cancer</title>
                    <description>A genetic vulnerability in clear cell renal cell carcinoma, the most aggressive type of kidney cancer, may lend itself to a combination treatment strategy that causes the cancer cells to self-destruct, according to recent research published in the Proceedings of the National Academy of Sciences.</description>
                    <link>https://medicalxpress.com/news/2026-09-combination-therapy-emerges-treatment-aggressive.html</link>
                    <category></category>
                    <pubDate>Wed, 30 Sep 2026 17:40:01 EDT</pubDate>
                    <guid isPermaLink="false">news710000703</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/combination-therapy-em.jpg" width="90" height="90" />
                                    </item>
                    </channel>
</rss>
